Elite in Hypophosphatasia (HPP)

Lothar Seefried

Wuerzburg, BY, DE 
Elite in Hypophosphatasia (HPP)
Wuerzburg, BY, DE 
OverviewLocationsClinical Research

Overview

Lothar Seefried practices in Wuerzburg, Germany. Mr. Seefried is rated as an Elite expert by MediFind in the treatment of Hypophosphatasia (HPP). His top areas of expertise are Hypophosphatasia (HPP), Rickets, Hypophosphatemia, X-Linked Hypophosphatemia, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 82 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 37 articles and participated in 1 clinical trial in the study of Hypophosphatasia (HPP).

Gender
Male

Locations

Wuerzburg, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Identification of Longitudinal Burden of Disease and Functional Impairment in X-Linked Hypophosphatemia
Identification of Longitudinal Burden of Disease and Functional Impairment in X-Linked Hypophosphatemia
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Other
A Prospective, Bi-centric,Randomized, Primary Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome
A Prospective, Bi-centric,Randomized, Primary Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome
Enrollment Status: Completed
Publish Date: August 13, 2024
Intervention Type: Drug
Study Phase: Phase 3
An Investigator-sponsored Phase 3b Open-label Study of Anti- FGF23 Antibody Burosumab (KRN23) in Adult Patients With Xlinked Hypophosphatemia (XLH) in GERmany - BurGER
An Investigator-sponsored Phase 3b Open-label Study of Anti- FGF23 Antibody Burosumab (KRN23) in Adult Patients With Xlinked Hypophosphatemia (XLH) in GERmany - BurGER
Enrollment Status: Completed
Publish Date: May 03, 2023
Intervention Type: Drug
Study Drug: Burosumab
Study Phase: Phase 3
Exploratory Evaluation of the Potential for Long-term Retention of Gadolinium in the Bones of Patients Who Have Received Gadolinium Based Contrast Agents According to Their Medical History
Exploratory Evaluation of the Potential for Long-term Retention of Gadolinium in the Bones of Patients Who Have Received Gadolinium Based Contrast Agents According to Their Medical History
Enrollment Status: Completed
Publish Date: September 28, 2022
Intervention Type: Procedure
Study Phase: Not Applicable
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) Observational Study
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) Observational Study
Enrollment Status: Completed
Publish Date: December 29, 2021
View 4 Less Clinical Trials

82 Total Publications

XLH Matters 2024: expert insights and practical tools for enhancing care of people living with X-linked hypophosphataemia.
XLH Matters 2024: expert insights and practical tools for enhancing care of people living with X-linked hypophosphataemia.
Journal: Orphanet journal of rare diseases
Published: September 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Seefried's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile